COVID-19 Impact on Global PARP Inhibitors for Breast Cancer Market Size, Status and Forecast 2020-2026

July 2020 | 95 pages | ID: CDEF4E268941EN
QYResearch

Abstracts

This report focuses on the global PARP Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PARP Inhibitors for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• AstraZeneca
• Everest Pharmaceuticals
• Pfizer

Market segment by Type, the product can be split into

• Olaparib
• Talazoparib

Market segment by Application, split into

• Hospital
• Clinic
• Drug Center
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global PARP Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players.
• To present the PARP Inhibitors for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of PARP Inhibitors for Breast Cancer are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by PARP Inhibitors for Breast Cancer Revenue
1.4 Market Analysis by Type
  1.4.1 Global PARP Inhibitors for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Olaparib
  1.4.3 Talazoparib
1.5 Market by Application
  1.5.1 Global PARP Inhibitors for Breast Cancer Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Clinic
  1.5.4 Drug Center
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): PARP Inhibitors for Breast Cancer Industry Impact
  1.6.1 How the Covid-19 is Affecting the PARP Inhibitors for Breast Cancer Industry
    1.6.1.1 PARP Inhibitors for Breast Cancer Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and PARP Inhibitors for Breast Cancer Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for PARP Inhibitors for Breast Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 PARP Inhibitors for Breast Cancer Market Perspective (2015-2026)
2.2 PARP Inhibitors for Breast Cancer Growth Trends by Regions
  2.2.1 PARP Inhibitors for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 PARP Inhibitors for Breast Cancer Historic Market Share by Regions (2015-2020)
  2.2.3 PARP Inhibitors for Breast Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 PARP Inhibitors for Breast Cancer Market Growth Strategy
  2.3.6 Primary Interviews with Key PARP Inhibitors for Breast Cancer Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top PARP Inhibitors for Breast Cancer Players by Market Size
  3.1.1 Global Top PARP Inhibitors for Breast Cancer Players by Revenue (2015-2020)
  3.1.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Players (2015-2020)
  3.1.3 Global PARP Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global PARP Inhibitors for Breast Cancer Market Concentration Ratio
  3.2.1 Global PARP Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by PARP Inhibitors for Breast Cancer Revenue in 2019
3.3 PARP Inhibitors for Breast Cancer Key Players Head office and Area Served
3.4 Key Players PARP Inhibitors for Breast Cancer Product Solution and Service
3.5 Date of Enter into PARP Inhibitors for Breast Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global PARP Inhibitors for Breast Cancer Historic Market Size by Type (2015-2020)
4.2 Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Type (2021-2026)

5 PARP INHIBITORS FOR BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)
5.2 Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America PARP Inhibitors for Breast Cancer Market Size (2015-2020)
6.2 PARP Inhibitors for Breast Cancer Key Players in North America (2019-2020)
6.3 North America PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
6.4 North America PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe PARP Inhibitors for Breast Cancer Market Size (2015-2020)
7.2 PARP Inhibitors for Breast Cancer Key Players in Europe (2019-2020)
7.3 Europe PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
7.4 Europe PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

8 CHINA

8.1 China PARP Inhibitors for Breast Cancer Market Size (2015-2020)
8.2 PARP Inhibitors for Breast Cancer Key Players in China (2019-2020)
8.3 China PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
8.4 China PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan PARP Inhibitors for Breast Cancer Market Size (2015-2020)
9.2 PARP Inhibitors for Breast Cancer Key Players in Japan (2019-2020)
9.3 Japan PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
9.4 Japan PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia PARP Inhibitors for Breast Cancer Market Size (2015-2020)
10.2 PARP Inhibitors for Breast Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

11 INDIA

11.1 India PARP Inhibitors for Breast Cancer Market Size (2015-2020)
11.2 PARP Inhibitors for Breast Cancer Key Players in India (2019-2020)
11.3 India PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
11.4 India PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America PARP Inhibitors for Breast Cancer Market Size (2015-2020)
12.2 PARP Inhibitors for Breast Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020)
12.4 Central & South America PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 AstraZeneca
  13.1.1 AstraZeneca Company Details
  13.1.2 AstraZeneca Business Overview and Its Total Revenue
  13.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Introduction
  13.1.4 AstraZeneca Revenue in PARP Inhibitors for Breast Cancer Business (2015-2020))
  13.1.5 AstraZeneca Recent Development
13.2 Everest Pharmaceuticals
  13.2.1 Everest Pharmaceuticals Company Details
  13.2.2 Everest Pharmaceuticals Business Overview and Its Total Revenue
  13.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Introduction
  13.2.4 Everest Pharmaceuticals Revenue in PARP Inhibitors for Breast Cancer Business (2015-2020)
  13.2.5 Everest Pharmaceuticals Recent Development
13.3 Pfizer
  13.3.1 Pfizer Company Details
  13.3.2 Pfizer Business Overview and Its Total Revenue
  13.3.3 Pfizer PARP Inhibitors for Breast Cancer Introduction
  13.3.4 Pfizer Revenue in PARP Inhibitors for Breast Cancer Business (2015-2020)
  13.3.5 Pfizer Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. PARP Inhibitors for Breast Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by PARP Inhibitors for Breast Cancer Revenue
Table 3. Ranking of Global Top PARP Inhibitors for Breast Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global PARP Inhibitors for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Olaparib
Table 6. Key Players of Talazoparib
Table 7. COVID-19 Impact Global Market: (Four PARP Inhibitors for Breast Cancer Market Size Forecast Scenarios)
Table 8. Opportunities and Trends for PARP Inhibitors for Breast Cancer Players in the COVID-19 Landscape
Table 9. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 10. Key Regions/Countries Measures against Covid-19 Impact
Table 11. Proposal for PARP Inhibitors for Breast Cancer Players to Combat Covid-19 Impact
Table 12. Global PARP Inhibitors for Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global PARP Inhibitors for Breast Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global PARP Inhibitors for Breast Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global PARP Inhibitors for Breast Cancer Market Share by Regions (2015-2020)
Table 16. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global PARP Inhibitors for Breast Cancer Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. PARP Inhibitors for Breast Cancer Market Growth Strategy
Table 22. Main Points Interviewed from Key PARP Inhibitors for Breast Cancer Players
Table 23. Global PARP Inhibitors for Breast Cancer Revenue by Players (2015-2020) (Million US$)
Table 24. Global PARP Inhibitors for Breast Cancer Market Share by Players (2015-2020)
Table 25. Global Top PARP Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2019)
Table 26. Global PARP Inhibitors for Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players PARP Inhibitors for Breast Cancer Product Solution and Service
Table 29. Date of Enter into PARP Inhibitors for Breast Cancer Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 32. Global PARP Inhibitors for Breast Cancer Market Size Share by Type (2015-2020)
Table 33. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2021-2026)
Table 34. Global PARP Inhibitors for Breast Cancer Market Size Share by Application (2015-2020)
Table 35. Global PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 36. Global PARP Inhibitors for Breast Cancer Market Size Share by Application (2021-2026)
Table 37. North America Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 38. North America Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 39. North America PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 40. North America PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 41. North America PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 42. North America PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 43. Europe Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 45. Europe PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 46. Europe PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 47. Europe PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 48. Europe PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 49. China Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 50. China Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 51. China PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 52. China PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 53. China PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 54. China PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 55. Japan Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 57. Japan PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 58. Japan PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 59. Japan PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 60. Japan PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 63. Southeast Asia PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 65. Southeast Asia PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 67. India Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 68. India Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 69. India PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 70. India PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 71. India PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 72. India PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 73. Central & South America Key Players PARP Inhibitors for Breast Cancer Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players PARP Inhibitors for Breast Cancer Market Share (2019-2020)
Table 75. Central & South America PARP Inhibitors for Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America PARP Inhibitors for Breast Cancer Market Share by Type (2015-2020)
Table 77. Central & South America PARP Inhibitors for Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America PARP Inhibitors for Breast Cancer Market Share by Application (2015-2020)
Table 79. AstraZeneca Company Details
Table 80. AstraZeneca Business Overview
Table 81. AstraZeneca Product
Table 82. AstraZeneca Revenue in PARP Inhibitors for Breast Cancer Business (2015-2020) (Million US$)
Table 83. AstraZeneca Recent Development
Table 84. Everest Pharmaceuticals Company Details
Table 85. Everest Pharmaceuticals Business Overview
Table 86. Everest Pharmaceuticals Product
Table 87. Everest Pharmaceuticals Revenue in PARP Inhibitors for Breast Cancer Business (2015-2020) (Million US$)
Table 88. Everest Pharmaceuticals Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in PARP Inhibitors for Breast Cancer Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global PARP Inhibitors for Breast Cancer Market Share by Type: 2020 VS 2026
Figure 2. Olaparib Features
Figure 3. Talazoparib Features
Figure 4. Global PARP Inhibitors for Breast Cancer Market Share by Application: 2020 VS 2026
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Drug Center Case Studies
Figure 8. Other Case Studies
Figure 9. PARP Inhibitors for Breast Cancer Report Years Considered
Figure 10. Global PARP Inhibitors for Breast Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global PARP Inhibitors for Breast Cancer Market Share by Regions: 2020 VS 2026
Figure 12. Global PARP Inhibitors for Breast Cancer Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global PARP Inhibitors for Breast Cancer Market Share by Players in 2019
Figure 15. Global Top PARP Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2019
Figure 16. The Top 10 and 5 Players Market Share by PARP Inhibitors for Breast Cancer Revenue in 2019
Figure 17. North America PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America PARP Inhibitors for Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. AstraZeneca Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2015-2020)
Figure 26. Everest Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Everest Pharmaceuticals Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2015-2020)
Figure 28. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Pfizer Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2015-2020)
Figure 30. Bottom-up and Top-down Approaches for This Report
Figure 31. Data Triangulation
Figure 32. Key Executives Interviewed